Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Lymphocytic, Chronic, B-Cell | 100 | 2024 | 1596 | 17.840 |
Why?
|
Sulfonamides | 41 | 2024 | 1932 | 6.100 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 31 | 2024 | 1434 | 4.920 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 13 | 2024 | 1377 | 2.940 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 42 | 2023 | 11472 | 2.830 |
Why?
|
Antineoplastic Agents | 39 | 2024 | 13655 | 2.580 |
Why?
|
Pyrimidines | 23 | 2023 | 2933 | 2.200 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 3 | 2021 | 180 | 2.120 |
Why?
|
Pyrazoles | 18 | 2021 | 1970 | 2.120 |
Why?
|
Lymphoma, Mantle-Cell | 8 | 2021 | 233 | 2.100 |
Why?
|
Adenine | 20 | 2024 | 936 | 2.000 |
Why?
|
Piperidines | 22 | 2024 | 1602 | 1.880 |
Why?
|
Quinazolinones | 8 | 2021 | 221 | 1.870 |
Why?
|
Protein Kinase Inhibitors | 23 | 2023 | 5522 | 1.830 |
Why?
|
Vidarabine | 5 | 2024 | 345 | 1.820 |
Why?
|
Benzamides | 7 | 2021 | 1378 | 1.800 |
Why?
|
Purines | 12 | 2021 | 593 | 1.790 |
Why?
|
Hematologic Neoplasms | 10 | 2023 | 1820 | 1.740 |
Why?
|
Lymphoma, Non-Hodgkin | 6 | 2023 | 1379 | 1.710 |
Why?
|
Pyrazines | 6 | 2021 | 1231 | 1.670 |
Why?
|
Molecular Targeted Therapy | 10 | 2020 | 2723 | 1.540 |
Why?
|
Lymphoma, Follicular | 5 | 2023 | 435 | 1.380 |
Why?
|
Phosphatidylinositol 3-Kinases | 8 | 2024 | 2938 | 1.230 |
Why?
|
Protein-Tyrosine Kinases | 7 | 2017 | 2455 | 1.220 |
Why?
|
Leukemia, Prolymphocytic, T-Cell | 3 | 2024 | 21 | 1.220 |
Why?
|
Lymphoma, B-Cell | 7 | 2024 | 930 | 1.080 |
Why?
|
Chromosomes, Human, Pair 17 | 6 | 2018 | 438 | 1.070 |
Why?
|
Cyclophosphamide | 6 | 2024 | 2236 | 1.040 |
Why?
|
Drug Resistance, Neoplasm | 18 | 2024 | 5163 | 0.970 |
Why?
|
Hematopoietic Stem Cell Transplantation | 15 | 2023 | 5425 | 0.950 |
Why?
|
Chromosome Deletion | 8 | 2018 | 1400 | 0.920 |
Why?
|
Apoptosis | 18 | 2024 | 9715 | 0.880 |
Why?
|
Lymphoma | 6 | 2021 | 1873 | 0.810 |
Why?
|
Splenic Neoplasms | 1 | 2021 | 100 | 0.750 |
Why?
|
Neoplasm Proteins | 5 | 2021 | 3691 | 0.740 |
Why?
|
Receptors, Antigen, B-Cell | 4 | 2019 | 547 | 0.720 |
Why?
|
Pneumocystis carinii | 1 | 2020 | 74 | 0.700 |
Why?
|
Smith-Magenis Syndrome | 5 | 2018 | 19 | 0.680 |
Why?
|
Chromosome Aberrations | 4 | 2019 | 1811 | 0.680 |
Why?
|
Isoquinolines | 5 | 2021 | 368 | 0.680 |
Why?
|
Humans | 158 | 2024 | 742088 | 0.670 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2020 | 247 | 0.650 |
Why?
|
Bone Marrow Diseases | 2 | 2010 | 230 | 0.640 |
Why?
|
Hematology | 1 | 2021 | 219 | 0.610 |
Why?
|
Recurrence | 11 | 2023 | 8333 | 0.610 |
Why?
|
Genes, Immunoglobulin Heavy Chain | 1 | 2017 | 57 | 0.610 |
Why?
|
Stromal Cells | 2 | 2013 | 1353 | 0.590 |
Why?
|
In Situ Hybridization, Fluorescence | 5 | 2021 | 2638 | 0.590 |
Why?
|
Opportunistic Infections | 1 | 2020 | 389 | 0.580 |
Why?
|
Waldenstrom Macroglobulinemia | 3 | 2021 | 1052 | 0.580 |
Why?
|
Tumor Suppressor Protein p53 | 5 | 2019 | 2948 | 0.560 |
Why?
|
Neutropenia | 4 | 2023 | 891 | 0.500 |
Why?
|
Mitochondria | 7 | 2020 | 3520 | 0.490 |
Why?
|
Sequence Deletion | 1 | 2018 | 1526 | 0.470 |
Why?
|
MAP Kinase Signaling System | 1 | 2021 | 1525 | 0.470 |
Why?
|
Radioactive Hazard Release | 2 | 2010 | 14 | 0.470 |
Why?
|
Aged | 57 | 2022 | 162944 | 0.460 |
Why?
|
Chromosomes, Human | 1 | 2015 | 457 | 0.440 |
Why?
|
Signal Transduction | 10 | 2023 | 23387 | 0.440 |
Why?
|
Safety | 1 | 2017 | 1185 | 0.440 |
Why?
|
Lymphoproliferative Disorders | 1 | 2016 | 525 | 0.420 |
Why?
|
Irritable Bowel Syndrome | 1 | 2017 | 445 | 0.420 |
Why?
|
Gastrointestinal Tract | 1 | 2018 | 814 | 0.410 |
Why?
|
Leukemia, Myeloid, Acute | 5 | 2023 | 3497 | 0.390 |
Why?
|
Aged, 80 and over | 34 | 2021 | 57683 | 0.390 |
Why?
|
Nephelometry and Turbidimetry | 1 | 2010 | 91 | 0.380 |
Why?
|
Myelodysplastic-Myeloproliferative Diseases | 1 | 2010 | 12 | 0.380 |
Why?
|
Immunoglobulin lambda-Chains | 1 | 2010 | 87 | 0.370 |
Why?
|
Remission Induction | 7 | 2021 | 2384 | 0.370 |
Why?
|
Nuclear Weapons | 1 | 2010 | 13 | 0.370 |
Why?
|
Immunoglobulin kappa-Chains | 1 | 2010 | 172 | 0.360 |
Why?
|
Stem Cell Transplantation | 4 | 2023 | 1618 | 0.360 |
Why?
|
Drug Administration Schedule | 6 | 2021 | 4929 | 0.350 |
Why?
|
Disease-Free Survival | 12 | 2022 | 6891 | 0.350 |
Why?
|
Aniline Compounds | 3 | 2024 | 983 | 0.350 |
Why?
|
Middle Aged | 51 | 2022 | 213127 | 0.350 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2023 | 9185 | 0.350 |
Why?
|
Warfarin | 1 | 2017 | 1493 | 0.340 |
Why?
|
Male | 59 | 2022 | 349538 | 0.330 |
Why?
|
Treatment Outcome | 24 | 2024 | 62966 | 0.330 |
Why?
|
Haploinsufficiency | 1 | 2010 | 329 | 0.320 |
Why?
|
Antigens, CD20 | 2 | 2021 | 198 | 0.320 |
Why?
|
Administration, Oral | 5 | 2019 | 3913 | 0.320 |
Why?
|
Survival Rate | 11 | 2022 | 12773 | 0.310 |
Why?
|
Mutation | 14 | 2024 | 29717 | 0.310 |
Why?
|
Renal Dialysis | 1 | 2017 | 1780 | 0.310 |
Why?
|
Patient Simulation | 1 | 2010 | 308 | 0.300 |
Why?
|
Mass Casualty Incidents | 1 | 2010 | 181 | 0.300 |
Why?
|
Neoplasm, Residual | 6 | 2023 | 974 | 0.300 |
Why?
|
Terrorism | 1 | 2010 | 211 | 0.300 |
Why?
|
Disaster Planning | 2 | 2010 | 549 | 0.290 |
Why?
|
Female | 58 | 2022 | 379592 | 0.290 |
Why?
|
Gene Expression Regulation, Leukemic | 5 | 2021 | 651 | 0.290 |
Why?
|
Carcinoma, Merkel Cell | 2 | 2014 | 299 | 0.280 |
Why?
|
Antibodies, Monoclonal | 5 | 2023 | 9274 | 0.270 |
Why?
|
Graft vs Host Disease | 5 | 2020 | 2951 | 0.270 |
Why?
|
Salvage Therapy | 3 | 2020 | 1269 | 0.270 |
Why?
|
bcl-X Protein | 2 | 2024 | 411 | 0.260 |
Why?
|
Transplantation, Homologous | 5 | 2019 | 4771 | 0.260 |
Why?
|
Bone Marrow Transplantation | 2 | 2010 | 2763 | 0.260 |
Why?
|
Cell Communication | 1 | 2012 | 1619 | 0.260 |
Why?
|
Thionucleotides | 2 | 2017 | 107 | 0.250 |
Why?
|
B-Lymphocytes | 3 | 2023 | 4664 | 0.250 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2018 | 319 | 0.250 |
Why?
|
Nitriles | 2 | 2021 | 952 | 0.250 |
Why?
|
Adult | 42 | 2021 | 213712 | 0.250 |
Why?
|
Leukemia | 3 | 2018 | 1507 | 0.240 |
Why?
|
Apoptosis Regulatory Proteins | 2 | 2023 | 1158 | 0.240 |
Why?
|
Lymphocytes | 1 | 2012 | 2614 | 0.240 |
Why?
|
Cell Line, Tumor | 9 | 2024 | 16665 | 0.240 |
Why?
|
Hodgkin Disease | 2 | 2021 | 1413 | 0.230 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2017 | 2195 | 0.230 |
Why?
|
Prognosis | 13 | 2021 | 29010 | 0.230 |
Why?
|
Neoplasms | 6 | 2023 | 21596 | 0.230 |
Why?
|
Follow-Up Studies | 8 | 2024 | 39004 | 0.230 |
Why?
|
Etoposide | 2 | 2022 | 637 | 0.230 |
Why?
|
Proto-Oncogene Proteins | 5 | 2018 | 4553 | 0.220 |
Why?
|
Receptors, CXCR4 | 3 | 2021 | 726 | 0.220 |
Why?
|
Myelodysplastic Syndromes | 2 | 2023 | 1351 | 0.220 |
Why?
|
Radiation Injuries | 1 | 2010 | 1178 | 0.220 |
Why?
|
Chemokine CXCL12 | 2 | 2016 | 462 | 0.210 |
Why?
|
Pseudopseudohypoparathyroidism | 1 | 2001 | 9 | 0.210 |
Why?
|
Leukemia, Prolymphocytic | 1 | 2021 | 7 | 0.210 |
Why?
|
Enzyme Inhibitors | 1 | 2013 | 3800 | 0.210 |
Why?
|
Health Services Needs and Demand | 1 | 2010 | 1411 | 0.200 |
Why?
|
TNF Receptor-Associated Factor 4 | 1 | 2021 | 5 | 0.200 |
Why?
|
Proto-Oncogene Proteins c-bcr | 1 | 2021 | 20 | 0.200 |
Why?
|
Immunoglobulin Heavy Chains | 3 | 2019 | 659 | 0.200 |
Why?
|
Drug Screening Assays, Antitumor | 3 | 2021 | 731 | 0.190 |
Why?
|
Doxorubicin | 3 | 2022 | 2215 | 0.190 |
Why?
|
Pyrimethamine | 1 | 2021 | 98 | 0.190 |
Why?
|
Chlorambucil | 1 | 2020 | 43 | 0.190 |
Why?
|
T-Lymphocytes, Regulatory | 3 | 2023 | 2986 | 0.190 |
Why?
|
Tumor Lysis Syndrome | 2 | 2017 | 42 | 0.180 |
Why?
|
Cytogenetics | 2 | 2017 | 203 | 0.180 |
Why?
|
Transplantation, Autologous | 6 | 2023 | 2123 | 0.180 |
Why?
|
Animals | 19 | 2024 | 168561 | 0.180 |
Why?
|
Class Ib Phosphatidylinositol 3-Kinase | 1 | 2020 | 30 | 0.180 |
Why?
|
Vincristine | 1 | 2022 | 1036 | 0.180 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2021 | 8425 | 0.180 |
Why?
|
Prednisone | 2 | 2022 | 1567 | 0.170 |
Why?
|
Myeloproliferative Disorders | 2 | 2016 | 603 | 0.170 |
Why?
|
Atrial Fibrillation | 1 | 2017 | 5019 | 0.170 |
Why?
|
Epoxy Compounds | 1 | 2018 | 136 | 0.160 |
Why?
|
Pyrroles | 2 | 2017 | 1143 | 0.160 |
Why?
|
Drug Evaluation, Preclinical | 2 | 2014 | 1372 | 0.160 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2024 | 3557 | 0.160 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3130 | 0.160 |
Why?
|
Retreatment | 1 | 2019 | 604 | 0.160 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 3236 | 0.150 |
Why?
|
Peptide Fragments | 3 | 2017 | 5095 | 0.150 |
Why?
|
Disease Progression | 9 | 2023 | 13256 | 0.150 |
Why?
|
Kaplan-Meier Estimate | 5 | 2020 | 6534 | 0.150 |
Why?
|
Macrolides | 1 | 2018 | 201 | 0.150 |
Why?
|
Gossypol | 1 | 2017 | 23 | 0.150 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2021 | 600 | 0.150 |
Why?
|
Lymphocytosis | 1 | 2018 | 119 | 0.150 |
Why?
|
Methylprednisolone | 1 | 2018 | 388 | 0.150 |
Why?
|
Clinical Trials as Topic | 4 | 2020 | 7901 | 0.140 |
Why?
|
TOR Serine-Threonine Kinases | 3 | 2023 | 2107 | 0.140 |
Why?
|
Drug Eruptions | 1 | 2019 | 295 | 0.140 |
Why?
|
STAT3 Transcription Factor | 1 | 2021 | 874 | 0.140 |
Why?
|
Th17 Cells | 1 | 2023 | 765 | 0.140 |
Why?
|
Indoles | 2 | 2017 | 1834 | 0.140 |
Why?
|
Piperazines | 4 | 2016 | 2488 | 0.140 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 1 | 2017 | 97 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2016 | 193 | 0.140 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2023 | 2940 | 0.140 |
Why?
|
Virus Activation | 1 | 2018 | 319 | 0.140 |
Why?
|
Congresses as Topic | 1 | 2021 | 764 | 0.140 |
Why?
|
Combined Modality Therapy | 3 | 2018 | 8621 | 0.130 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2020 | 890 | 0.130 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2018 | 627 | 0.130 |
Why?
|
Drug Synergism | 2 | 2017 | 1791 | 0.130 |
Why?
|
Immunotherapy | 4 | 2023 | 4414 | 0.130 |
Why?
|
Tissue Banks | 1 | 2016 | 183 | 0.130 |
Why?
|
Oxidative Stress | 2 | 2020 | 3081 | 0.130 |
Why?
|
Thrombocytopenia | 1 | 2023 | 1171 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-myc | 2 | 2021 | 987 | 0.130 |
Why?
|
Hematologic Diseases | 1 | 2019 | 498 | 0.130 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2023 | 4438 | 0.130 |
Why?
|
Neoplasm Staging | 6 | 2020 | 11001 | 0.130 |
Why?
|
Exanthema | 1 | 2019 | 488 | 0.130 |
Why?
|
Quality-Adjusted Life Years | 1 | 2021 | 1679 | 0.130 |
Why?
|
DNA Mutational Analysis | 2 | 2017 | 4187 | 0.130 |
Why?
|
Nitrophenols | 2 | 2012 | 172 | 0.130 |
Why?
|
Scleroderma, Diffuse | 1 | 2014 | 16 | 0.130 |
Why?
|
Hepatitis B virus | 1 | 2018 | 513 | 0.120 |
Why?
|
Time Factors | 6 | 2021 | 40054 | 0.120 |
Why?
|
DNA Damage | 2 | 2021 | 2423 | 0.120 |
Why?
|
Cross-Over Studies | 1 | 2020 | 2030 | 0.120 |
Why?
|
United States | 10 | 2021 | 69693 | 0.120 |
Why?
|
Karyotyping | 1 | 2016 | 1243 | 0.120 |
Why?
|
Treatment Failure | 1 | 2020 | 2615 | 0.120 |
Why?
|
Mice | 10 | 2024 | 81045 | 0.120 |
Why?
|
Transplantation Immunology | 1 | 2016 | 547 | 0.120 |
Why?
|
Skin Neoplasms | 2 | 2014 | 5662 | 0.120 |
Why?
|
Anemia | 1 | 2023 | 1499 | 0.120 |
Why?
|
Autoimmunity | 1 | 2021 | 1348 | 0.120 |
Why?
|
Antifungal Agents | 1 | 2018 | 729 | 0.120 |
Why?
|
Anti-Inflammatory Agents | 2 | 2020 | 1788 | 0.110 |
Why?
|
T-Lymphocytes | 3 | 2021 | 10163 | 0.110 |
Why?
|
Quinoxalines | 1 | 2015 | 288 | 0.110 |
Why?
|
Alternative Splicing | 1 | 2018 | 1118 | 0.110 |
Why?
|
Registries | 4 | 2020 | 8077 | 0.110 |
Why?
|
Bone Marrow | 2 | 2020 | 2941 | 0.110 |
Why?
|
Tumor Cells, Cultured | 3 | 2021 | 6313 | 0.110 |
Why?
|
Triazoles | 1 | 2018 | 907 | 0.110 |
Why?
|
Health Care Surveys | 1 | 2020 | 2451 | 0.110 |
Why?
|
Bayes Theorem | 1 | 2020 | 2303 | 0.110 |
Why?
|
Hepatitis B | 1 | 2018 | 695 | 0.110 |
Why?
|
Antiviral Agents | 2 | 2021 | 2978 | 0.100 |
Why?
|
Transplantation Conditioning | 2 | 2019 | 1597 | 0.100 |
Why?
|
Saccharomyces cerevisiae Proteins | 1 | 2001 | 1884 | 0.100 |
Why?
|
Lymph Nodes | 2 | 2014 | 3465 | 0.100 |
Why?
|
Comorbidity | 4 | 2020 | 10372 | 0.100 |
Why?
|
Membrane Potential, Mitochondrial | 1 | 2012 | 297 | 0.100 |
Why?
|
Bence Jones Protein | 1 | 2010 | 18 | 0.100 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2012 | 349 | 0.100 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2018 | 1183 | 0.100 |
Why?
|
Blood Protein Electrophoresis | 1 | 2010 | 73 | 0.100 |
Why?
|
Biphenyl Compounds | 2 | 2012 | 914 | 0.100 |
Why?
|
Retrospective Studies | 11 | 2022 | 77098 | 0.100 |
Why?
|
Myeloma Proteins | 1 | 2010 | 70 | 0.100 |
Why?
|
Immunity, Cellular | 1 | 2017 | 1606 | 0.100 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2021 | 10943 | 0.090 |
Why?
|
Densitometry | 1 | 2010 | 156 | 0.090 |
Why?
|
Boston | 2 | 2021 | 9305 | 0.090 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2012 | 441 | 0.090 |
Why?
|
Cost of Illness | 1 | 2020 | 1852 | 0.090 |
Why?
|
CD4 Lymphocyte Count | 1 | 2016 | 2557 | 0.090 |
Why?
|
Immunoglobulin Variable Region | 2 | 2023 | 421 | 0.090 |
Why?
|
Government Agencies | 1 | 2010 | 156 | 0.090 |
Why?
|
Hemoglobinuria, Paroxysmal | 1 | 2010 | 102 | 0.090 |
Why?
|
Fatal Outcome | 2 | 2017 | 1849 | 0.090 |
Why?
|
Blood Banks | 1 | 2010 | 110 | 0.090 |
Why?
|
Myocarditis | 1 | 2017 | 770 | 0.090 |
Why?
|
Half-Life | 1 | 2010 | 658 | 0.090 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2022 | 9941 | 0.090 |
Why?
|
Serum | 1 | 2010 | 212 | 0.090 |
Why?
|
Phosphopyruvate Hydratase | 1 | 2009 | 135 | 0.080 |
Why?
|
Hospital Bed Capacity | 1 | 2010 | 213 | 0.080 |
Why?
|
Interinstitutional Relations | 1 | 2010 | 240 | 0.080 |
Why?
|
Prospective Studies | 7 | 2022 | 53187 | 0.080 |
Why?
|
Cost-Benefit Analysis | 1 | 2021 | 5385 | 0.080 |
Why?
|
Societies, Medical | 1 | 2021 | 3740 | 0.080 |
Why?
|
Relief Work | 1 | 2010 | 137 | 0.080 |
Why?
|
Civil Defense | 1 | 2010 | 109 | 0.080 |
Why?
|
Coculture Techniques | 1 | 2012 | 1341 | 0.080 |
Why?
|
Health Planning | 1 | 2010 | 237 | 0.080 |
Why?
|
Anemia, Aplastic | 1 | 2010 | 226 | 0.080 |
Why?
|
Survival Analysis | 5 | 2020 | 10248 | 0.080 |
Why?
|
Lung Neoplasms | 2 | 2024 | 13019 | 0.080 |
Why?
|
Paraproteinemias | 1 | 2010 | 247 | 0.080 |
Why?
|
Keratins | 1 | 2009 | 515 | 0.080 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2012 | 2906 | 0.080 |
Why?
|
Abdomen | 1 | 2014 | 1107 | 0.080 |
Why?
|
Indazoles | 1 | 2009 | 287 | 0.080 |
Why?
|
Age Factors | 3 | 2020 | 18355 | 0.080 |
Why?
|
Immunoglobulin M | 1 | 2012 | 1538 | 0.080 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2009 | 379 | 0.070 |
Why?
|
Pyridines | 1 | 2018 | 2818 | 0.070 |
Why?
|
Scalp | 1 | 2009 | 380 | 0.070 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2013 | 933 | 0.070 |
Why?
|
Cytarabine | 2 | 2020 | 684 | 0.070 |
Why?
|
Lung Diseases, Interstitial | 1 | 2014 | 807 | 0.070 |
Why?
|
BRCA2 Protein | 1 | 2011 | 790 | 0.070 |
Why?
|
Pandemics | 3 | 2020 | 8328 | 0.070 |
Why?
|
Clone Cells | 2 | 2021 | 1692 | 0.070 |
Why?
|
Dendritic Cells | 1 | 2016 | 2723 | 0.070 |
Why?
|
Oxidation-Reduction | 2 | 2021 | 2187 | 0.070 |
Why?
|
MicroRNAs | 1 | 2021 | 3731 | 0.060 |
Why?
|
Point Mutation | 1 | 2010 | 1624 | 0.060 |
Why?
|
Translocation, Genetic | 1 | 2010 | 1417 | 0.060 |
Why?
|
Bone Marrow Cells | 1 | 2012 | 2513 | 0.060 |
Why?
|
Drug Therapy, Combination | 3 | 2021 | 6483 | 0.060 |
Why?
|
BRCA1 Protein | 1 | 2011 | 1145 | 0.060 |
Why?
|
Myocardium | 1 | 2017 | 4775 | 0.060 |
Why?
|
Amyloidosis | 1 | 2010 | 795 | 0.060 |
Why?
|
Fetal Blood | 1 | 2010 | 1317 | 0.060 |
Why?
|
Academic Medical Centers | 2 | 2014 | 2749 | 0.060 |
Why?
|
International Cooperation | 1 | 2010 | 1421 | 0.060 |
Why?
|
Chemokine CCL4 | 1 | 2023 | 128 | 0.060 |
Why?
|
Cause of Death | 1 | 2014 | 3571 | 0.060 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 3239 | 0.060 |
Why?
|
Triage | 1 | 2010 | 977 | 0.060 |
Why?
|
Protein Biosynthesis | 1 | 2010 | 2126 | 0.050 |
Why?
|
Culture Media, Conditioned | 1 | 2023 | 533 | 0.050 |
Why?
|
Muridae | 1 | 2001 | 61 | 0.050 |
Why?
|
Immunophenotyping | 2 | 2019 | 1866 | 0.050 |
Why?
|
Cohort Studies | 4 | 2017 | 40450 | 0.050 |
Why?
|
STAT6 Transcription Factor | 1 | 2021 | 199 | 0.050 |
Why?
|
Azacitidine | 1 | 2023 | 347 | 0.050 |
Why?
|
Tumor Microenvironment | 2 | 2023 | 3564 | 0.050 |
Why?
|
DNA Repair | 1 | 2010 | 2042 | 0.050 |
Why?
|
Bleomycin | 1 | 2021 | 499 | 0.050 |
Why?
|
Chromosomes, Human, Pair 2 | 1 | 2001 | 326 | 0.050 |
Why?
|
Vinblastine | 1 | 2021 | 490 | 0.050 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2001 | 261 | 0.040 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2023 | 491 | 0.040 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 694 | 0.040 |
Why?
|
Cell Proliferation | 3 | 2021 | 10472 | 0.040 |
Why?
|
Disease Management | 2 | 2021 | 2450 | 0.040 |
Why?
|
Safety-Based Drug Withdrawals | 1 | 2019 | 38 | 0.040 |
Why?
|
Gene Expression Profiling | 3 | 2021 | 9410 | 0.040 |
Why?
|
Jurkat Cells | 1 | 2020 | 742 | 0.040 |
Why?
|
DNA | 1 | 2013 | 7289 | 0.040 |
Why?
|
Drug Repositioning | 1 | 2021 | 229 | 0.040 |
Why?
|
Neoplasm Metastasis | 1 | 2009 | 4839 | 0.040 |
Why?
|
Dacarbazine | 1 | 2021 | 567 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2022 | 839 | 0.040 |
Why?
|
Emergency Medical Services | 1 | 2010 | 1914 | 0.040 |
Why?
|
Spliceosomes | 1 | 2018 | 110 | 0.040 |
Why?
|
Protein Binding | 1 | 2010 | 9387 | 0.040 |
Why?
|
Immunization, Passive | 1 | 2020 | 625 | 0.040 |
Why?
|
Interleukin-4 | 1 | 2021 | 1146 | 0.040 |
Why?
|
Leukemia, Myeloid | 1 | 2021 | 705 | 0.040 |
Why?
|
Base Sequence | 1 | 2009 | 12797 | 0.040 |
Why?
|
Membrane Proteins | 1 | 2015 | 7873 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2022 | 1661 | 0.040 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2021 | 571 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 2 | 2018 | 20086 | 0.040 |
Why?
|
Oxidative Phosphorylation | 1 | 2019 | 480 | 0.040 |
Why?
|
Serine | 1 | 2020 | 828 | 0.040 |
Why?
|
Young Adult | 6 | 2019 | 56350 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 6259 | 0.040 |
Why?
|
Leukocytes, Mononuclear | 1 | 2023 | 1835 | 0.040 |
Why?
|
Mitogens | 1 | 2016 | 232 | 0.030 |
Why?
|
Models, Biological | 1 | 2012 | 9581 | 0.030 |
Why?
|
Biopsy | 2 | 2019 | 6756 | 0.030 |
Why?
|
Histiocytic Sarcoma | 1 | 2016 | 44 | 0.030 |
Why?
|
Gene Rearrangement | 1 | 2021 | 1179 | 0.030 |
Why?
|
Fluorouracil | 1 | 2020 | 1615 | 0.030 |
Why?
|
Leukemia, Experimental | 1 | 2016 | 246 | 0.030 |
Why?
|
Leukocyte Count | 1 | 2019 | 1583 | 0.030 |
Why?
|
Cell Transdifferentiation | 1 | 2016 | 171 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2010 | 14720 | 0.030 |
Why?
|
Antibodies | 1 | 2023 | 2459 | 0.030 |
Why?
|
Oligodeoxyribonucleotides | 1 | 2016 | 708 | 0.030 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 740 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2023 | 2502 | 0.030 |
Why?
|
Cisplatin | 1 | 2020 | 1637 | 0.030 |
Why?
|
Hepatitis, Autoimmune | 1 | 2016 | 141 | 0.030 |
Why?
|
Maximum Tolerated Dose | 1 | 2017 | 891 | 0.030 |
Why?
|
Internationality | 1 | 2020 | 1002 | 0.030 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 222 | 0.030 |
Why?
|
Diagnostic Errors | 1 | 2021 | 1255 | 0.030 |
Why?
|
Thiophenes | 1 | 2018 | 590 | 0.030 |
Why?
|
Genes, p53 | 1 | 2016 | 755 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 380 | 0.030 |
Why?
|
DNA Copy Number Variations | 1 | 2021 | 1940 | 0.030 |
Why?
|
Reactive Oxygen Species | 1 | 2020 | 2077 | 0.030 |
Why?
|
Methylnitronitrosoguanidine | 1 | 2012 | 20 | 0.030 |
Why?
|
Chromosome Mapping | 1 | 2001 | 4742 | 0.030 |
Why?
|
Cell Cycle | 1 | 2021 | 2964 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2010 | 19862 | 0.030 |
Why?
|
Flow Cytometry | 1 | 2023 | 5975 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2016 | 2085 | 0.030 |
Why?
|
Lymphocyte Subsets | 1 | 2013 | 315 | 0.030 |
Why?
|
Mice, Inbred C57BL | 2 | 2018 | 21821 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2016 | 1875 | 0.020 |
Why?
|
Random Allocation | 1 | 2016 | 2425 | 0.020 |
Why?
|
Thalidomide | 1 | 2016 | 888 | 0.020 |
Why?
|
Selection, Genetic | 1 | 2016 | 914 | 0.020 |
Why?
|
Calcium Channel Blockers | 1 | 2014 | 689 | 0.020 |
Why?
|
Inflammation | 2 | 2021 | 10578 | 0.020 |
Why?
|
Biological Products | 1 | 2020 | 856 | 0.020 |
Why?
|
Lymphocyte Count | 1 | 2013 | 792 | 0.020 |
Why?
|
Forecasting | 1 | 2020 | 2948 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2021 | 5519 | 0.020 |
Why?
|
Hydroxychloroquine | 1 | 2014 | 408 | 0.020 |
Why?
|
Founder Effect | 1 | 2011 | 190 | 0.020 |
Why?
|
Radiography, Abdominal | 1 | 2014 | 537 | 0.020 |
Why?
|
Respiratory Function Tests | 1 | 2014 | 1613 | 0.020 |
Why?
|
Algorithms | 1 | 2010 | 13853 | 0.020 |
Why?
|
Chromatin | 1 | 2021 | 2917 | 0.020 |
Why?
|
Phosphoproteins | 1 | 2018 | 2440 | 0.020 |
Why?
|
Phosphorylation | 1 | 2020 | 8436 | 0.020 |
Why?
|
Proton Pump Inhibitors | 1 | 2014 | 521 | 0.020 |
Why?
|
Jews | 1 | 2011 | 385 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 3585 | 0.020 |
Why?
|
Neoplasms, Second Primary | 1 | 2016 | 1052 | 0.020 |
Why?
|
Molecular Sequence Data | 1 | 2001 | 18112 | 0.020 |
Why?
|
Energy Metabolism | 1 | 2019 | 2896 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2014 | 2970 | 0.020 |
Why?
|
Cell Lineage | 1 | 2016 | 2504 | 0.020 |
Why?
|
Up-Regulation | 1 | 2016 | 4211 | 0.020 |
Why?
|
Cell Death | 1 | 2012 | 1695 | 0.020 |
Why?
|
Cytokines | 1 | 2021 | 7317 | 0.020 |
Why?
|
Cell Survival | 1 | 2016 | 5872 | 0.020 |
Why?
|
Health Care Costs | 1 | 2020 | 3203 | 0.020 |
Why?
|
Receptors, Progesterone | 1 | 2011 | 1097 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2021 | 13029 | 0.020 |
Why?
|
Proteome | 1 | 2016 | 1790 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2018 | 9735 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2016 | 2183 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2014 | 3612 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2023 | 11470 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2011 | 17400 | 0.020 |
Why?
|
Macrophages | 1 | 2020 | 5655 | 0.020 |
Why?
|
Risk Assessment | 2 | 2019 | 23320 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2014 | 6365 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2014 | 2107 | 0.020 |
Why?
|
Tissue Donors | 1 | 2014 | 2205 | 0.020 |
Why?
|
Antirheumatic Agents | 1 | 2014 | 1335 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2018 | 12017 | 0.020 |
Why?
|
Internet | 1 | 2016 | 3062 | 0.010 |
Why?
|
Electrocardiography | 1 | 2017 | 6440 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2011 | 20774 | 0.010 |
Why?
|
Cell Nucleus | 1 | 2012 | 2968 | 0.010 |
Why?
|
Receptors, Estrogen | 1 | 2011 | 2186 | 0.010 |
Why?
|
Child | 1 | 2010 | 77478 | 0.010 |
Why?
|
Receptor, erbB-2 | 1 | 2011 | 2410 | 0.010 |
Why?
|
Gene Expression | 1 | 2014 | 7790 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2016 | 14554 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 7276 | 0.010 |
Why?
|
Patient Selection | 1 | 2012 | 4214 | 0.010 |
Why?
|
Liver | 1 | 2016 | 7470 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2014 | 12242 | 0.010 |
Why?
|
Research Design | 1 | 2016 | 5979 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2018 | 18006 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2014 | 12344 | 0.010 |
Why?
|
Chronic Disease | 1 | 2014 | 9144 | 0.010 |
Why?
|
Phenotype | 1 | 2016 | 16331 | 0.010 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2014 | 4029 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2014 | 21719 | 0.010 |
Why?
|
Melanoma | 1 | 2014 | 5462 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2012 | 15530 | 0.010 |
Why?
|
Adolescent | 1 | 2016 | 85649 | 0.000 |
Why?
|
Risk Factors | 1 | 2012 | 72145 | 0.000 |
Why?
|